Main endpoint not met in sozinibercept ShORe, COAST trials
August 23, 2025
3 min watch
LONG BEACH, Calif. — On this video from the American Society of Retina Specialists annual assembly, Charles C. Wykoff, MD, PhD, FASRS, discusses sozinibercept mixture remedy within the part 3 ShORe and COAST trials.
The first endpoint was not met in both examine, which mixed sozinibercept (Opthea) with ranibizumab or aflibercept for the therapy of neovascular age-related macular degeneration.
“This was a sturdy part 3 medical trial program involving practically 2,000 sufferers,” Wykoff, of Retina Consultants of Texas, informed Healio. “On this program, sozinibercept together with aflibercept or ranibizumab didn’t enhance visible or anatomic outcomes in neovascular AMD administration in comparison with both aflibercept or ranibizumab alone.”
Sources/Disclosures
Collapse
Wykoff CC. COAST: A part 3 examine of intravitreal sozinibercept mixed with aflibercept in members with neovascular age-related macular degeneration. Introduced at: American Society of Retina Specialists annual assembly; July 30-Aug. 2, 2025; Lengthy Seaside, California.
Disclosures:
Wykoff stories being co-chair of the COAST examine.
